Trial Profile
A multi-center, randomised, double-blind, placebo-controlled phase III clinical trial to evaluate the protective efficacy, safety and immunogenicity of Recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine (Hansenulapolymorpha)quadri recomb in healthy Chinese woman aged 18-45 years
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 08 Jun 2018
Price :
$35
*
At a glance
- Drugs Human papillomavirus vaccine quadrivalent Chengdu institute of biological product (Primary)
- Indications Cervical cancer
- Focus Registrational; Therapeutic Use
- Sponsors Chengdu Institute of Biological Products
- 08 Jun 2018 New trial record